CAMBRIDGE, Mass.--(BUSINESS WIRE)--Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced that it has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry.
"We are honored to be selected as a Fierce 15 company, reflecting the immense potential of our approach to designing novel therapies by integrating best-in-class computational and experimental methods to visualize protein motion," said Sanjiv K. Patel, M.D., Relay's President and Chief Executive Officer. "Our talented team is leading a pragmatic revolution as we make rapid progress by leveraging our knowledge of protein motion. These insights will guide Relay as we develop breakthrough medicines that will make a transformative difference for patients. We are privileged to be included among the 2017 'Fierce 15' class."
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. Every year FierceBiotech evaluates hundreds of private companies from around the world for inclusion on its annual Fierce 15 list. Selection is based on a variety of factors including the strength of a company’s technology, partnerships, venture backers, and competitive market position.
This is FierceBiotech’s fifteenth annual Fierce 15 selection. A complete list of ‘Fierce 15’ companies can be found online at http://www.fiercebiotech.com/special-report/fiercebiotech-s-2017-fierce-15.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
About Relay Therapeutics
Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach and focusing on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016 with $57 million in Series A financing from Third Rock Ventures and an affiliate of D. E. Shaw Research.